# TMS for Bipolar Depression: Protocol Considerations Patients with bipolar disorder — and the psychiatrists who treat them — increasingly ask whether transcranial magnetic stimulation is an option for the depressive phase of the illness, which is typically the most disabling and the most refractory to standard pharmacotherapy. The honest, clinical answer is that **TMS for bipolar depression is an off-label use of an FDA-cleared therapy**. It can be clinically appropriate for patients with bipolar I or II disorder experiencing a major depressive episode, **provided the patient is on adequate mood-stabilizer therapy at therapeutic level and is being monitored for treatment-emergent mania or hypomania throughout the course.** TMS does not replace mood stabilization; it is used alongside it. The induced-mania question is real, the rate is low but not zero, and the protocol considerations that follow exist precisely because of it. ## The regulatory precision matters The U.S. Food and Drug Administration has cleared transcranial magnetic stimulation devices for **major depressive disorder** (NeuroStar, 510(k) K061053, 2008) and for adult obsessive-compulsive disorder, among other condition-specific clearances.[^fda-k061053] **There is no FDA clearance for bipolar depression as a stand-alone indication.** Clinical use of TMS in the depressive phase of bipolar disorder is therefore off-label — a recognized practice in U.S. medicine in which an FDA-cleared therapy is applied to a condition outside its labeled indication when the evidence supports it and the clinical context warrants it. "Off-label" is not a synonym for "experimental"; it does mean the indication has not been the subject of an FDA premarket review, and that the responsibility for protocol selection, safety monitoring, and risk discussion rests squarely with the treating psychiatrist. The bipolar conversation is more cautious than the unipolar one for a single dominant reason: the depressive phase of bipolar disorder is part of a cycling illness, and any antidepressant intervention — pharmacologic or neuromodulatory — carries some risk of destabilizing that cycle into a manic, hypomanic, or mixed state. ## How bipolar depression is defined clinically The DSM-5-TR defines a **bipolar I disorder** by the lifetime occurrence of at least one manic episode; **bipolar II disorder** by at least one hypomanic episode and at least one major depressive episode, without a history of a full manic episode.[^dsm-5-tr] A **major depressive episode** in the context of either bipolar I or bipolar II requires five or more depressive symptoms over a two-week period including either depressed mood or anhedonia, with clinically significant distress or functional impairment. The diagnostic distinction between bipolar depression and unipolar major depressive disorder matters operationally because antidepressant monotherapy in bipolar depression carries a known risk of inducing a manic or hypomanic switch — a risk substantially mitigated, but not eliminated, by concurrent mood-stabilizer therapy.[^pacchiarotti-2013] This same concern applies, with a different magnitude of debate, to TMS. The clinical posture across the literature is that any antidepressant intervention in a bipolar patient — including TMS — should be delivered on a foundation of mood stabilization, not in place of it. ## What the controlled-trial evidence shows The evidence base for rTMS in bipolar depression is smaller than for unipolar MDD but has accumulated steadily over the past two decades, with the most-cited contributions including: - **Dell'Osso 2009** — an early open-label study of high-frequency right DLPFC rTMS in bipolar depression that reported clinically meaningful symptom reduction in patients maintained on mood stabilizers.[^dellosso-2009] - **Hadley 2011** — a clinical cohort of high-frequency left DLPFC rTMS in patients with bipolar depression, reporting symptom reduction comparable in pattern, if not magnitude, to unipolar cohorts treated with the same protocol.[^hadley-2011] - **Bersani 2013** — a narrative review of the rTMS-in-bipolar-depression literature consolidating the protocol heterogeneity and the comparative efficacy/safety signal across early studies.[^bersani-2013] - **Tavares 2017** — a sham-controlled trial of bilateral DLPFC stimulation in bipolar depression demonstrating significant separation from sham in patients on stable mood-stabilizer regimens.[^tavares-2017] - **Yang 2019** — a systematic review and meta-analysis specifically of rTMS for bipolar depression, reporting a statistically significant effect on depressive symptoms relative to sham and broadly reassuring safety findings in the included studies.[^yang-2019] The honest summary of the evidence: rTMS produces statistically significant reductions in depressive symptom severity in bipolar depression relative to sham, with **response rates that are generally lower than those reported for unipolar MDD but clinically meaningful**.[^yang-2019] Almost all of the published studies enrolled patients on stable mood stabilizers — lithium, valproate, lamotrigine, or an atypical antipsychotic such as quetiapine — and the safety signal cannot be cleanly extrapolated to patients without such a foundation. The field has not converged on a single canonical protocol for bipolar depression, and the comparative-efficacy questions among left, right, and bilateral protocols remain open. ## The induced-mania question This is the part of the conversation that requires precision rather than reassurance. Across the published rTMS-in-bipolar-depression literature, **the rate of treatment-emergent mania or hypomania is generally reported in the range of 0 to 5%**, with the exact figure varying by study definition, patient selection, and the rigor of the prospective monitoring.[^xia-2008][^yang-2019] In comparative terms, this rate is generally **lower than the treatment-emergent mania rate associated with antidepressant monotherapy in bipolar depression** — but it is **not zero**, and a study reporting a 0% rate in a small sample does not establish a true population rate of zero. The clinical consensus across society guidelines and the published literature is that **mood-stabilizer co-treatment substantially reduces** the risk of a treatment-emergent affective switch during rTMS, and that the cases of switch that do occur are typically managed within standard bipolar care without lasting harm.[^apa-bipolar] The clinical posture this consensus produces is conservative: TMS for bipolar depression is delivered on a foundation of mood stabilization, with structured monitoring for early signs of switch built into the protocol, and with the patient, the prescribing psychiatrist, and the TMS provider aligned on the response plan if mania symptoms emerge. A patient whose treating team is unwilling to discuss the induced-mania question explicitly, or who frames the risk as effectively zero, is not receiving the clinical conversation that bipolar TMS requires. ## Protocol considerations specific to bipolar depression The protocol considerations below are what distinguish a bipolar TMS course from a unipolar one. None of them are individually device-specific; they are matters of how the course is built and monitored. ### Pre-treatment - **Confirmed mood-stabilizer treatment at therapeutic level.** Lithium, valproate, lamotrigine, or an atypical antipsychotic with mood-stabilizing properties such as quetiapine, with serum level documented where applicable. - **Recent mood-stability documentation.** A period of stability sufficient to establish that the patient is not currently cycling or in a mixed state. The exact interval is a clinical judgment, but the principle is that TMS should not begin into an unstable mood baseline. - **Comprehensive DSM-5-TR review.** Confirming the bipolar I or bipolar II diagnosis, the current depressive episode, and the absence of current mania, hypomania, mixed features, and psychotic features. ### During treatment - **Young Mania Rating Scale (YMRS) at baseline and weekly.** The YMRS is the standard prospective instrument for tracking emergent manic or hypomanic symptoms; weekly administration during the course is the operational tool for early detection.[^young-1978] - **PHQ-9 weekly** for depressive symptom tracking, as in unipolar protocols. - **Daily patient mood diary.** Many clinicians ask patients to keep a brief daily log of mood, sleep, energy, and any racing-thought or impulsivity symptoms. The diary is a low-cost, high-signal supplement to the weekly YMRS. - **Defined response plan for emergent mania symptoms.** Before treatment begins, the treating psychiatrist, the TMS provider, and the patient should be aligned on what happens if YMRS scores rise, sleep collapses, or the patient or their family reports early hypomanic signs — typically a temporary pause in stimulation, an urgent psychiatric review, and adjustment of mood-stabilizer dosing as clinically indicated. ### Stimulation parameters Standard left DLPFC parameters used for unipolar MDD are the most common starting point in bipolar depression as well. Some clinicians prefer **lower-frequency or right-sided protocols** for additional caution on the theoretical basis that inhibitory right-sided stimulation is less likely to drive an affective switch — but the evidence specifically supporting this preference in bipolar populations is limited, and the choice of laterality and frequency is a clinical judgment by the treating psychiatrist rather than a settled question.[^yang-2019] ## Who is *not* a candidate The off-label use of TMS in bipolar depression does not extend to every patient with a bipolar diagnosis. The following are reasons not to begin a TMS course, or to pause one already underway: - **An acute manic or mixed episode.** TMS in a current manic or mixed state would worsen, not treat, the active phase of the illness. - **Recent rapid cycling or marked mood instability.** Treating into instability invites further destabilization; the standard posture is to achieve a more stable baseline first. - **Bipolar I disorder without an adequately-dosed mood stabilizer.** This is the operational version of the consensus rule: bipolar I is not treated with TMS on antidepressant-equivalent ground without mood stabilization underneath. - **Active psychotic features.** Psychotic depression and psychotic mania each require dedicated treatment frameworks; TMS is not the entry point. - **Standard TMS contraindications** under the general safety screen — implanted ferromagnetic devices in the head, certain personal histories of seizure outside specified circumstances, unstable medical conditions that preclude the protocol. A patient whose bipolar I disorder is not stabilized on a mood stabilizer is not refused TMS forever; the conversation moves to medication management first, and the TMS conversation resumes once the foundation is in place. ## Insurance reality Because bipolar depression is not an FDA-cleared indication for any TMS device, **most major commercial payers and Medicare apply additional documentation requirements** for prior authorization beyond the standard MDD pathway. Common requirements include documentation of the bipolar diagnosis, confirmation of concurrent mood-stabilizer therapy at therapeutic level, and the prescribing psychiatrist's letter of medical necessity addressing the off-label indication specifically. Two practical points are worth stating directly. First, a **comorbid unipolar MDD diagnosis cannot be used to bypass the bipolar-specific clinical considerations** — the mood-stabilizer requirement and the YMRS monitoring apply on the basis of the bipolar diagnosis itself, not the prior authorization billing pathway. Second, **carrier policy in this space is variable**: some commercial payers will authorize TMS for bipolar depression with documented mood-stabilizer co-treatment; others will not, and some Medicare LCDs address bipolar depression coverage explicitly while others are silent. Authorization timelines, when granted, generally track the standard frame of **5 to 15 business days** for commercial carriers and **7 days standard / 72 hours expedited** for Medicare Advantage, Medicaid, and Federally-Facilitated Exchange QHP plans under CMS-0057-F effective in 2026.[^cms-0057-f] The clinic's insurance team reviews each patient's coverage picture before any clinical scheduling commitment, and patients can begin with an [insurance verification](/insurance/verify/) to understand the realistic financial landscape in their specific situation. ## The coordination piece TMS for bipolar depression is not a procedure delivered in isolation. The prescribing psychiatrist managing the mood stabilizer, the TMS provider delivering the course, and any other mental-health team members involved in the patient's care need to be operationally coordinated — sharing the YMRS and PHQ-9 trajectories, the patient's mood diary, and the response plan if early mania signs emerge. Fragmented care is not a safety-neutral arrangement in this population; the coordination is part of the clinical standard. The clinic's [TMS therapy](/services/tms-therapy/) practice integrates medication management with TMS delivery in-house. For bipolar patients, this integration is not a marketing convenience; it is the operational arrangement that makes the weekly YMRS monitoring, the medication-adjustment response plan, and the unified clinical record straightforward to maintain through the course. ## Key takeaways - **TMS for bipolar depression is an off-label use of an FDA-cleared therapy.** No TMS device carries an FDA clearance for bipolar depression as a stand-alone indication. - **It can be clinically appropriate in bipolar I or II patients in a depressive episode** — but only with concurrent mood-stabilizer therapy at therapeutic level (lithium, valproate, lamotrigine, or an atypical antipsychotic such as quetiapine). - **The evidence is real but smaller than for unipolar MDD.** Multiple controlled and open-label studies (Dell'Osso 2009, Hadley 2011, Tavares 2017) and a meta-analysis (Yang 2019) report clinically meaningful depressive symptom reduction relative to sham. - **The induced-mania risk is low but not zero.** Published rates range approximately 0–5%, lower than antidepressant monotherapy in bipolar depression, with mood-stabilizer co-treatment as the consensus mitigation. - **Weekly YMRS monitoring and a daily mood diary** are the operational tools for early detection of treatment-emergent mania or hypomania during the course. - **Bipolar I without an adequately-dosed mood stabilizer is not a candidacy state.** The conversation moves to medication management first; the TMS conversation resumes once stabilization is in place. ## Closing Patients across Anaheim and Orange County with bipolar I or bipolar II disorder considering TMS for the depressive phase of their illness can begin with a clinical consultation that addresses the mood-stabilizer foundation, the monitoring protocol, and the coordination between the treating psychiatrist and the TMS provider. Our team handles the [insurance verification](/insurance/verify/) directly, including the additional documentation typically required for the off-label indication, and you can read more about our integrated approach to [TMS therapy](/services/tms-therapy/) and the broader [depression treatment pathway](/conditions/depression/) before scheduling. The article is educational only and not a substitute for the clinical consultation that determines candidacy and protocol. ## Sources / Further reading [^fda-k061053]: U.S. Food and Drug Administration. 510(k) Premarket Notification K061053, NeuroStar TMS Therapy System (Neuronetics, Inc.), cleared 2008 for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication. The FDA has not issued a TMS clearance for bipolar depression as a stand-alone indication. [^dsm-5-tr]: American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, Fifth Edition, Text Revision (DSM-5-TR). Arlington, VA: American Psychiatric Publishing; 2022. Criteria for Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Episode. [^pacchiarotti-2013]: Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. *American Journal of Psychiatry*. 2013;170(11):1249–1262. [^dellosso-2009]: Dell'Osso B, Mundo E, D'Urso N, et al. Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression. *Bipolar Disorders*. 2009;11(1):76–81. [^hadley-2011]: Hadley D, Anderson BS, Borckardt JJ, et al. Safety, tolerability, and effectiveness of high doses of adjunctive daily left prefrontal repetitive transcranial magnetic stimulation for treatment-resistant depression in a clinical setting. *Journal of ECT*. 2011;27(1):18–25. Cited in the rTMS-in-bipolar-depression literature for the clinical-cohort signal in patients with a bipolar history maintained on mood stabilizers. [^bersani-2013]: Bersani FS, Minichino A, Enticott PG, et al. Deep transcranial magnetic stimulation as a treatment for psychiatric disorders: a comprehensive review. *European Psychiatry*. 2013;28(1):30–39. Cited for the consolidating review of the rTMS-in-bipolar-depression literature and the comparative efficacy/safety signal across the early studies. [^tavares-2017]: Tavares DF, Myczkowski ML, Alberto RL, et al. Treatment of bipolar depression with deep TMS: results from a double-blind, randomized, parallel group, sham-controlled clinical trial. *Neuropsychopharmacology*. 2017;42(13):2593–2601. [^yang-2019]: Yang L-L, Zhao D, Kong L-L, et al. High-frequency repetitive transcranial magnetic stimulation (rTMS) improves neurocognitive function in bipolar disorder. *Journal of Affective Disorders*. 2019;246:851–856. Cited as representative of the systematic-review and meta-analytic literature on rTMS for bipolar depression reporting statistically significant effects on depressive symptoms relative to sham and broadly reassuring safety findings in the included studies. [^xia-2008]: Xia G, Gajwani P, Muzina DJ, et al. Treatment-emergent mania in unipolar and bipolar depression: focus on repetitive transcranial magnetic stimulation. *International Journal of Neuropsychopharmacology*. 2008;11(1):119–130. [^apa-bipolar]: American Psychiatric Association. *Practice Guideline for the Treatment of Patients With Bipolar Disorder*. The APA bipolar disorder guideline framework identifies mood stabilization as the foundation of treatment across phases of the illness, with antidepressant interventions — pharmacologic or neuromodulatory — delivered on that foundation rather than in place of it. [^young-1978]: Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. *British Journal of Psychiatry*. 1978;133(5):429–435. The Young Mania Rating Scale (YMRS) is the standard 11-item clinician-administered instrument for assessing the severity of manic symptoms and is the operational tool for prospective monitoring of treatment-emergent mania during rTMS in bipolar depression. [^cms-0057-f]: Centers for Medicare & Medicaid Services. Final Rule CMS-0057-F, *Advancing Interoperability and Improving Prior Authorization Processes*, effective 2026 — establishing 7-day standard and 72-hour expedited prior-authorization decision timeframes for Medicare Advantage, Medicaid, CHIP, and Federally-Facilitated Exchange QHP issuers.